Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Sun Pharma new cholesterol drug deal to boost revenue, say brokerages

BUZZ-India's Sun Pharma new cholesterol drug deal to boost revenue, say brokerages

** Axis Capital ("add",PT: 2,100 rupees) estimates Sun Pharma's SUN.NS newly licensed cholesterol drug could generate more than $700 million in peak sales

** SUN signed an exclusive deal with LIB Therapeutics to manufacture and commercialise lerodalcibep worldwide, excluding the US and China; financial terms were not disclosed

** Axis says deal marks SUN's entry into fast-growing cholesterol-drug market and could benefit from co's expanded international reach following its acquisition of US-based Organon

** DAM Capital ("buy",PT: 2,269 rupees) says SUN could leverage Organon's established cardiovascular business outside the US to accelerate lerodalcibep's rollout

** SUN up as much as 1.32% at 1,862.30 rupees

** Rated "buy" on avg by 31 analysts, median PT at 2,150 rupees - LSEG-compiled data

** YTD stock up 7.75%


(Reporting by Surbhi Misra in Bengaluru)

((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))

Recent news on Sun Pharmaceutical Industries

See all news